

Giuseppe Procopio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3591872/publications.pdf>

Version: 2024-02-01

227
papers

11,737
citations

81900

39
h-index

30922

102
g-index

230
all docs

230
docs citations

230
times ranked

14190
citing authors

#	ARTICLE	IF	CITATIONS
1	Update on radioligand therapy with ¹⁷⁷ Lu-PSMA for metastatic castration-resistant prostate cancer: clinical aspects and survival effects. Tumori, 2022, 108, 315-325.	1.1	3
2	Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study. European Urology, 2022, 81, 274-282.	1.9	55
3	Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21). Expert Review of Anticancer Therapy, 2022, 22, 115-121.	2.4	5
4	PARP inhibitors and metastatic castration-resistant prostate cancer: future directions and pitfalls. Translational Oncology, 2022, 15, 101263.	3.7	2
5	Immunotherapy and Sonpavde score validation in advanced upper tract urothelial carcinoma: a retrospective study by the Italian Network for Research in Urologic-Oncology (Meet-URO group). Immunotherapy, 2022, 14, 107-114.	2.0	4
6	Biomarker-driven immunotherapy for precision medicine in prostate cancer. Personalized Medicine, 2022, 19, 51-66.	1.5	1
7	Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet-Uro 19BEYOND study. Cancer Medicine, 2022, 11, 3084-3092.	2.8	4
8	Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study. ESMO Open, 2022, 7, 100431.	4.5	1
9	Cabozantinib as First-line Treatment in Patients With Metastatic Collecting Duct Renal Cell Carcinoma. JAMA Oncology, 2022, 8, 910.	7.1	20
10	Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study. Journal of Personalized Medicine, 2022, 12, 727.	2.5	3
11	Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study. Cancers, 2022, 14, 2293.	3.7	4
12	Effects of cabozantinib on bone turnover markers in real-world metastatic renal cell carcinoma. Tumori, 2021, 107, 542-549.	1.1	4
13	Patient associations and clinical oncology research: how much does a patient's voice really matter?. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 433-440.	1.4	3
14	Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?. European Urology Oncology, 2021, 4, 274-281.	5.4	7
15	Second-line treatment in renal cell carcinoma: clinical experience and decision making. Therapeutic Advances in Urology, 2021, 13, 175628722110228.	2.0	6
16	Radical metastasectomy followed by sorafenib versus observation in patients with clear cell renal cell carcinoma: extended follow-up of efficacy results from the randomized phase II RESORT trial. Expert Review of Clinical Pharmacology, 2021, 14, 261-268.	3.1	8
17	Cabozantinib (Cabo) beyond progression improves survival in advanced renal cell carcinoma patients: The CABEYOND study (Meet-Uro 21).. Journal of Clinical Oncology, 2021, 39, 320-320.	1.6	1
18	Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. New England Journal of Medicine, 2021, 384, 1289-1300.	27.0	956

#	ARTICLE	IF	CITATIONS
19	Impact of Previous Nephrectomy on Clinical Outcome of Metastatic Renal Carcinoma Treated With Immune-Oncology: A Real-World Study on Behalf of Meet-URO Group (MeetUro-7b). <i>Frontiers in Oncology</i> , 2021, 11, 682449.	2.8	16
20	Integrative Transcriptomic Analysis Reveals Distinctive Molecular Traits and Novel Subtypes of Collecting Duct Carcinoma. <i>Cancers</i> , 2021, 13, 2903.	3.7	7
21	Integrated transcriptionalâ€phenotypic analysis captures systemic immunomodulation following antiangiogenic therapy in renal cell carcinoma patients. <i>Clinical and Translational Medicine</i> , 2021, 11, e434.	4.0	3
22	Characteristics and Treatment Challenges of Non-Clear Cell Renal Cell Carcinoma. <i>Cancers</i> , 2021, 13, 3807.	3.7	17
23	Clinical outcome of renal cancer patients who early interrupted immunotherapy due to serious immune-related adverse events. Meet-Uro 13 trial on behalf of the MeetUro investigators. <i>Journal of Translational Medicine</i> , 2021, 19, 328.	4.4	4
24	Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro) Tj ETQq0 0,0 rgBT /Qverlock 10	1.9	3
25	ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma. <i>Annals of Oncology</i> , 2021, 32, 1511-1519.	1.2	113
26	Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110196.	3.2	36
27	Clinical Outcomes of Metastatic Renal Carcinoma Following Disease Progression to Programmed Death (PD)-1 or PD-L1 Inhibitors (IO). <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 121-125.	1.3	12
28	GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreak. <i>Therapeutic Advances in Urology</i> , 2021, 13, 175628722110543.	2.0	3
29	Renal Cancer. UNIPA Springer Series, 2021, , 755-774.	0.1	1
30	First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series. <i>World Journal of Clinical Oncology</i> , 2021, 12, 1037-1046.	2.3	2
31	Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 395-405.	1.6	450
32	Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors. <i>Cancers</i> , 2020, 12, 84.	3.7	22
33	Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with longâ€term followâ€up of the randomized, openâ€label, phase 3 CheckMate 025 trial. <i>Cancer</i> , 2020, 126, 4156-4167.	4.1	201
34	Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis. <i>Targeted Oncology</i> , 2020, 15, 495-501.	3.6	28
35	<p>Immunotherapeutic Targets and Therapy for Renal Cell Carcinoma</p>. <i>ImmunoTargets and Therapy</i> , 2020, Volume 9, 273-288.	5.8	9
36	Effectiveness of abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer in a large prospective real-world cohort: the ABItude study. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592096872.	3.2	6

#	ARTICLE	IF	CITATIONS
37	The emerging role of PARP inhibitors in prostate cancer. Expert Review of Anticancer Therapy, 2020, 20, 715-726.	2.4	12
38	Patients with sarcomatoid renal cell carcinoma “ re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors. European Journal of Cancer, 2020, 136, 195-203.	2.8	47
39	Pembrolizumab plus axitinib: another step ahead in advanced renal cell carcinoma. Lancet Oncology, The, 2020, 21, 1538-1539.	10.7	7
40	Prospective Translational Study Investigating Molecular PrEdictors of Resistance to First-Line Pazopanib in Metastatic reNal CELL Carcinoma (PIPELINE Study). American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 621-627.	1.3	4
41	Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer. Frontiers in Oncology, 2020, 10, 1644.	2.8	48
42	Use of a natural multicomponent mouthwash plus oral hygiene vs oral hygiene alone to prevent everolimus-induced stomatitis: the STOP multicenter, randomized trial. Tumori, 2020, 106, 257-266.	1.1	2
43	Immune-checkpoint inhibitors and metastatic prostate cancer therapy: Learning by making mistakes. Cancer Treatment Reviews, 2020, 88, 102057.	7.7	28
44	Safety and activity of radium-223 in metastatic castration-resistant prostate cancer: the experience of Istituto Nazionale dei Tumori. Tumori, 2020, 106, 406-412.	1.1	5
45	Current Understanding of Urachal Adenocarcinoma and Management Strategy. Current Oncology Reports, 2020, 22, 9.	4.0	23
46	Angiogenesis and Immunity in Renal Carcinoma: Can We Turn an Unhappy Relationship into a Happy Marriage?. Journal of Clinical Medicine, 2020, 9, 930.	2.4	25
47	PROfound: Efficacy of olaparib (ola) by prior taxane use in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations.. Journal of Clinical Oncology, 2020, 38, 134-134.	1.6	6
48	Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme. BJU International, 2019, 123, 98-105.	2.5	70
49	Should we use combination therapy for all advanced renal cell carcinoma?. Lancet Oncology, The, 2019, 20, 1331-1332.	10.7	3
50	Do biomarkers play a predictive role for response to novel immunotherapeutic agents in metastatic renal cell carcinoma?. Expert Opinion on Biological Therapy, 2019, 19, 1107-1110.	3.1	6
51	Role and relevance of quality indicators in the selection of first-line treatment of patients with metastatic renal cell carcinoma: a position paper of the MeetURO Group. Future Oncology, 2019, 15, 2657-2666.	2.4	1
52	Management of kidney cancer patients: 2018 guidelines of the Italian Medical Oncology Association (AIOM). Tumori, 2019, 105, 3-12.	1.1	10
53	Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases. Prostate, 2019, 79, 1683-1691.	2.3	17
54	The Evaluation of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: Open Challenges in the Clinical Practice. International Journal of Molecular Sciences, 2019, 20, 4263.	4.1	17

#	ARTICLE	IF	CITATIONS
55	Collecting ducts carcinoma: An orphan disease. Literature overview and future perspectives. <i>Cancer Treatment Reviews</i> , 2019, 79, 101891.	7.7	22
56	Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study. <i>European Urology Oncology</i> , 2019, 2, 699-707.	5.4	38
57	Real-world Effectiveness and Safety of Pazopanib in Patients With Intermediate Prognostic Risk Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e526-e533.	1.9	9
58	Cabozantinib in Renal Cell Carcinoma With Brain Metastases: Safety and Efficacy in a Real-World Population. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 291-298.	1.9	30
59	The role of metastasectomy in advanced renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 603-611.	2.4	7
60	Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study). <i>Oncologist</i> , 2019, 24, 491-497.	3.7	22
61	Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab. <i>Clinical Cancer Research</i> , 2019, 25, 3839-3846.	7.0	147
62	Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program. , 2019, 7, 99.		110
63	Safety and Efficacy of Cabozantinib for Metastatic Nonclear Renal Cell Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 42-45.	1.3	20
64	Exposure to Multiple Lines of Treatment and Survival of Patients With Metastatic Renal Cell Carcinoma: A Real-world Analysis. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e735-e742.	1.9	14
65	Combination therapies for patients with metastatic renal cell carcinoma. <i>Lancet Oncology</i> , The, 2018, 19, 281-283.	10.7	4
66	Costo-Efficacia di cabozantinib nel trattamento di seconda linea del tumore a cellule renali metastatico (mRCC) in Italia. <i>Global & Regional Health Technology Assessment</i> , 2018, 2018, 228424031879073.	0.1	0
67	Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: the Italian Named Patient Program. <i>Future Oncology</i> , 2018, 14, 2691-2699.	2.4	3
68	Adjuvant treatment of high-risk renal cell carcinoma: the jury is still out. <i>Annals of Oncology</i> , 2018, 29, 2030-2032.	1.2	0
69	Negative prognostic factors and resulting clinical outcome in patients with metastatic renal cell carcinoma included in the Italian nivolumab-expanded access program. <i>Future Oncology</i> , 2018, 14, 1347-1354.	2.4	9
70	Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in Italy. <i>PLoS ONE</i> , 2018, 13, e0199642.	2.5	23
71	Surgery of locally advanced and metastatic kidney cancer after tyrosine kinase inhibitors therapy: single institute experience. <i>Tumori</i> , 2018, 104, 388-393.	1.1	2
72	Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e945-e951.	1.9	30

#	ARTICLE	IF	CITATIONS
73	Management of Metastatic Collecting Duct Carcinoma: An Encouraging Result in a Patient Treated With Cabozantinib. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e521-e523.	1.9	17
74	A randomized, open label, multicenter phase 2 study, to evaluate the efficacy of sorafenib (So) in patients (pts) with metastatic renal cell carcinoma (mRCC) after a radical resection of the metastases: RESORT trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4502-4502.	1.6	7
75	Does Fâ€18 ^FFDG</sup>â€PET</sup> still play a role in metastatic renal cell carcinoma?. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2017, 61, 250-251.	1.8	0
76	CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma. <i>European Urology</i> , 2017, 72, 962-971.	1.9	199
77	Everolimus treatment for neuroendocrine tumors: latest results and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 183-188.	3.2	20
78	Management of metastatic castration-resistant prostate cancer: A focus on radium-223. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 113, 43-51.	4.4	28
79	Multimodal treatment of advanced renal cancer in 2017. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 1395-1402.	3.1	23
80	Outcome of Patients with Renal Cell Carcinoma and Multiple Glandular Metastases Treated with Targeted Agents. <i>Oncology</i> , 2017, 92, 269-275.	1.9	5
81	Castration-naïve metastatic prostate cancer: reshaping old paradigms. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 879-881.	2.4	3
82	Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases. <i>Annals of Oncology</i> , 2017, 28, 2464-2471.	1.2	28
83	Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?. <i>Drugs in R and D</i> , 2017, 17, 461-467.	2.2	5
84	Personalized therapy in renal cell carcinoma: are the different tyrosine kinase inhibitors the same for any patient?. <i>Expert Review of Precision Medicine and Drug Development</i> , 2017, 2, 5-7.	0.7	3
85	Treatment of Advanced Renal Cell Carcinoma: Recent Advances and Current Role of Immunotherapy, Surgery, and Cryotherapy. <i>Tumori</i> , 2017, 103, 15-21.	1.1	8
86	Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis. <i>Oncotarget</i> , 2017, 8, 100708-100716.	1.8	32
87	Multidisciplinary Approach of Prostate Cancer Patients. , 2017, , 281-293.		0
88	Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy. <i>Drug Design, Development and Therapy</i> , 2016, Volume 10, 2167-2172.	4.3	15
89	Cabozantinib in advanced renal cell carcinoma: a METEOR impact on clinical practice. <i>Translational Andrology and Urology</i> , 2016, 5, 974-976.	1.4	2
90	Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective Analysis. <i>PLoS ONE</i> , 2016, 11, e0151662.	2.5	56

#	ARTICLE	IF	CITATIONS
91	Nivolumab in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience. Therapeutic Advances in Urology, 2016, 8, 319-326.	2.0	25
92	Immunotherapy advances in uro-genital malignancies. Critical Reviews in Oncology/Hematology, 2016, 105, 52-64.	4.4	19
93	Safety of long-term exposure to abiraterone acetate in patients with castration-resistant prostate cancer and concomitant cardiovascular risk factors. Therapeutic Advances in Medical Oncology, 2016, 8, 323-330.	3.2	13
94	Antisecretive and Antitumor Activity of Abiraterone Acetate in Human Adrenocortical Cancer: A Preclinical Study. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4594-4602.	3.6	31
95	Improved quality of life is the way to longer life. Lancet Oncology, The, 2016, 17, 862-863.	10.7	5
96	Adjuvant treatment for renal cell carcinoma: in the long run will we get the same answers?. Expert Review of Anticancer Therapy, 2016, 16, 803-804.	2.4	3
97	Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer. Future Oncology, 2016, 12, 493-502.	2.4	8
98	Treatment of elderly patients with metastatic renal cell carcinoma. Expert Review of Anticancer Therapy, 2016, 16, 323-334.	2.4	9
99	Evolving treatment landscape in metastatic renal cell carcinoma: where are we now?. Expert Review of Anticancer Therapy, 2016, 16, 133-135.	2.4	1
100	An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer. Investigational New Drugs, 2016, 34, 236-242.	2.6	21
101	Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme. Clinical Genitourinary Cancer, 2016, 14, 48-55.	1.9	14
102	Dual modulation of MCL-1 and mTOR determines the response to sunitinib. Journal of Clinical Investigation, 2016, 127, 153-168.	8.2	49
103	Analysis of overall survival by number of radium-223 injections received in an international expanded access program (iEAP).. Journal of Clinical Oncology, 2016, 34, 5082-5082.	1.6	20
104	Radium-223 (Ra-223) re-treatment (Re-tx): First experience from an international, multicenter, prospective study in patients (Pts) with castration-resistant prostate cancer and bone metastases (mCRPC).. Journal of Clinical Oncology, 2016, 34, 197-197.	1.6	13
105	CheckMate 025 phase III trial: Outcomes by key baseline factors and prior therapy for nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2016, 34, 498-498.	1.6	21
106	Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma. Oncotarget, 2016, 7, 33381-33390.	1.8	11
107	Predictors of long-term response to abiraterone in patients with metastatic castration-resistant prostate cancer: a retrospective cohort study. Oncotarget, 2016, 7, 40085-40094.	1.8	17
108	Urachal carcinoma: towards a precision medicine. Translational Cancer Research, 2016, 5, S1307-S1310.	1.0	5

#	ARTICLE	IF	CITATIONS
109	Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian Named Patient Programme. <i>BJU International</i> , 2015, 115, 764-771.	2.5	17
110	Predicting Molecular Models: Where Are We Going?. <i>EBioMedicine</i> , 2015, 2, 1594-1595.	6.1	0
111	Tokio Rationale and Protocol: A Phase II Study to Evaluate the Activity and Safety of Third-line Tyrosine Kinase Inhibitor after 2 Tyrosine Kinase Inhibitors in Patients with Metastatic Renal Cell Carcinoma. <i>Tumori</i> , 2015, 101, 701-703.	1.1	1
112	Safety of Abiraterone Acetate in Castration-resistant Prostate Cancer Patients With Concomitant Cardiovascular Risk Factors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 479-482.	1.3	26
113	Bone metastases affect prognosis but not effectiveness of third-line targeted therapies in patients with metastatic renal cell carcinoma. <i>Canadian Urological Association Journal</i> , 2015, 9, 263.	0.6	6
114	Sites of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first-line sunitinib or sorafenib. <i>Therapeutic Advances in Urology</i> , 2015, 7, 59-68.	2.0	2
115	Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. <i>European Urology</i> , 2015, 68, 147-153.	1.9	73
116	Prognostic Factors in Patients Receiving Third Line Targeted Therapy for Metastatic Renal Cell Carcinoma. <i>Journal of Urology</i> , 2015, 193, 1905-1910.	0.4	11
117	Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 10.	8.6	65
118	Surgical Resection Does Not Improve Survival in Patients with Renal Metastases to the Pancreas in the Era of Tyrosine Kinase Inhibitors. <i>Annals of Surgical Oncology</i> , 2015, 22, 2094-2100.	1.5	72
119	Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis. <i>Annals of Oncology</i> , 2015, 26, 2107-2113.	1.2	85
120	Clinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and younger. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 265.e15-265.e21.	1.6	6
121	Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors: Implications for clinical practice, trial design, and molecular interrogation. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 332.e19-332.e24.	1.6	12
122	Time from Nephrectomy as a Prognostic Factor in Metastatic Renal Cell Carcinoma Patients Receiving Targeted Therapies: Overall Results from a Large Cohort of Patients. <i>Oncology</i> , 2015, 88, 133-138.	1.9	4
123	Clinical Outcomes of Metastatic Poor Prognosis Germ Cell Tumors: Current Perspective From a Referral Center. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 385-391.e1.	1.9	4
124	Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. <i>Targeted Oncology</i> , 2015, 10, 517-522.	3.6	49
125	Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2015, 373, 1803-1813.	27.0	4,889
126	Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma. <i>Therapeutic Advances in Urology</i> , 2015, 7, 152-161.	2.0	27

#	ARTICLE	IF	CITATIONS
127	Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients. <i>Future Oncology</i> , 2015, 11, 2881-2891.	2.4	12
128	Everolimus and Temozolomide Are Not the Same Second-Line in Metastatic Renal Cell Carcinoma. A Systematic Review and Meta-Analysis of Literature Data. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 137-141.	1.9	28
129	Sunitinib, Pazopanib or Sorafenib for the Treatment of Patients with Late Relapsing Metastatic Renal Cell Carcinoma. <i>Journal of Urology</i> , 2015, 193, 41-47.	0.4	58
130	Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: An up-to-date review and meta-analysis of clinical trials. <i>International Journal of Cancer</i> , 2015, 136, 1-10.	5.1	47
131	The Changes of Lipid Metabolism in Advanced Renal Cell Carcinoma Patients Treated with Everolimus: A New Pharmacodynamic Marker?. <i>PLoS ONE</i> , 2015, 10, e0120427.	2.5	9
132	Inhibition of the VEGF/VEGFR Pathway Improves Survival in Advanced Kidney Cancer: A Systematic Review and Meta-Analysis. <i>Current Drug Targets</i> , 2015, 16, 164-170.	2.1	47
133	Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib.. <i>Canadian Urological Association Journal</i> , 2014, 8, 121.	0.6	8
134	Targeted treatments in advanced renal cell carcinoma: focus on axitinib. <i>Pharmacogenomics and Personalized Medicine</i> , 2014, 7, 107.	0.7	5
135	Axitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studies. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 497-510.	2.4	9
136	First line treatment of metastatic renal cell carcinoma. <i>Cancer Biology and Therapy</i> , 2014, 15, 19-21.	3.4	7
137	Response to Targeted Therapy in Urachal Adenocarcinoma. <i>Rare Tumors</i> , 2014, 6, 124-127.	0.6	20
138	Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2014, 10, 975-983.	2.4	43
139	Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting. <i>Future Oncology</i> , 2014, 10, 1741-1750.	2.4	12
140	Targeted therapies in advanced renal cell carcinoma: the role of metastatic sites as a prognostic factor. <i>Future Oncology</i> , 2014, 10, 1361-1372.	2.4	9
141	Butterfly and Renal Cell Cancer: Out of Chaos Comes Order. <i>Journal of Clinical Oncology</i> , 2014, 32, 3083-3083.	1.6	2
142	Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy. <i>British Journal of Clinical Pharmacology</i> , 2014, 77, 929-938.	2.4	65
143	Stratification of clear cell renal cell carcinoma by signaling pathway analysis. <i>Expert Review of Proteomics</i> , 2014, 11, 237-249.	3.0	9
144	Study design and clinical evidence in mRCC. <i>Cancer Biology and Therapy</i> , 2014, 15, 486-488.	3.4	2

#	ARTICLE	IF	CITATIONS
145	Safety profile and treatment response of everolimus in different solid tumors: an observational study. <i>Future Oncology</i> , 2014, 10, 1611-1617.	2.4	8
146	Article Commentary: Everolimus in Advanced Solid Tumors: When to Start, Early or Late?. <i>Tumori</i> , 2014, 100, e2-e3.	1.1	7
147	Everolimus in advanced solid tumors: when to start, early or late?. <i>Tumori</i> , 2014, 100, e2-3.	1.1	3
148	Rationale and Protocol of SOAP: A Phase II Study to Evaluate the Efficacy of Sorafenib as Second-Line Treatment after Pazopanib in Patients with Advanced Renal Cell Carcinoma. <i>Tumori</i> , 2014, 100, e282-e285.	1.1	0
149	Treatment of collecting duct carcinoma: current status and future perspectives. <i>Anticancer Research</i> , 2014, 34, 1027-30.	1.1	20
150	Sequential Tyrosine Kinase Inhibitors (TKIs) in metastatic renal cell carcinoma: results from a large cohort of patients. <i>Anticancer Research</i> , 2014, 34, 2395-8.	1.1	4
151	Rationale and protocol of SOAP: a phase II study to evaluate the efficacy of sorafenib as second-line treatment after pazopanib in patients with advanced renal cell carcinoma. <i>Tumori</i> , 2014, 100, e282-5.	1.1	0
152	Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: Results from a large patient cohort. <i>European Journal of Cancer</i> , 2013, 49, 2134-2142.	2.8	60
153	Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2? A meta-analysis of published trials. <i>Prostate Cancer and Prostatic Diseases</i> , 2013, 16, 323-327.	3.9	10
154	Prognostic Role of Pancreatic Metastases From Renal Cell Carcinoma: Results From an Italian Center. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 484-488.	1.9	41
155	Complete responses in advanced renal cell carcinoma: Utopia or real chance?. <i>Clinical and Experimental Nephrology</i> , 2013, 17, 151-152.	1.6	1
156	Predictors of Health-related Quality of Life and Adjustment to Prostate Cancer During Active Surveillance. <i>European Urology</i> , 2013, 64, 30-36.	1.9	81
157	Metastatic renal cell carcinoma: how to make the best sequencing decision after withdrawal for intolerance to a tyrosine kinase inhibitor. <i>Future Oncology</i> , 2013, 9, 831-843.	2.4	7
158	Patient approach in advanced/metastatic renal cell carcinoma: focus on the elderly population and treatment-related toxicity. <i>Future Oncology</i> , 2013, 9, 1599-1607.	2.4	7
159	Targeted Therapies and Survival: What We Can Learn from Studies in Advanced Renal Cell Carcinoma. <i>Oncology</i> , 2013, 84, 39-42.	1.9	4
160	Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial. <i>Annals of Oncology</i> , 2013, 24, 2967-2971.	1.2	22
161	Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis. <i>British Journal of Cancer</i> , 2013, 108, 311-318.	6.4	49
162	Natural History of Malignant Bone Disease in Renal Cancer: Final Results of an Italian Bone Metastasis Survey. <i>PLoS ONE</i> , 2013, 8, e83026.	2.5	66

#	ARTICLE	IF	CITATIONS
163	Optimizing further treatment choices in short- and long-term responders to first-line therapy for patients with advanced renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1089-1096.	2.4	5
164	Experience with sorafenib in the treatment of advanced renal cell carcinoma. <i>Therapeutic Advances in Urology</i> , 2012, 4, 303-313.	2.0	17
165	Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant. <i>Cancer Biology and Therapy</i> , 2012, 13, 1001-1008.	3.4	6
166	Prognostic factors for survival in patients with metastatic renal cell carcinoma treated with targeted therapies. <i>British Journal of Cancer</i> , 2012, 107, 1227-1232.	6.4	18
167	Post-docetaxel therapy in castration resistant prostate cancer – the forest is growing in the desert. <i>Therapeutic Advances in Urology</i> , 2012, 4, 107-111.	2.0	2
168	Abiraterone acetate in castration-resistant prostate cancer. <i>Anti-Cancer Drugs</i> , 2012, 23, 247-254.	1.4	7
169	Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: state-of-the-science. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1571-1577.	2.4	35
170	Sunitinib and Everolimus in Pancreatic Neuroendocrine Tumors. <i>Tumori</i> , 2012, 98, 394-394.	1.1	4
171	New Perspectives in Advanced Genitourinary Malignancies. <i>Tumori</i> , 2012, 98, 267-269.	1.1	3
172	Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma? Efficacy data from a retrospective analysis of 7 cases. <i>Clinical and Experimental Nephrology</i> , 2012, 16, 464-467.	1.6	33
173	Complete Response After Sequential Sunitinib-Sorafenib Treatment in a Patient With Renal Cell Carcinoma: A Case Report. <i>Clinical Genitourinary Cancer</i> , 2012, 10, 130-133.	1.9	3
174	Re: Camillo Porta, Emiliano Calvo, Miguel A. Climent, et al. Efficacy and Safety of Everolimus in Elderly Patients With Metastatic Renal Cell Carcinoma: An Exploratory Analysis of the Outcomes of Elderly Patients in the RECORD-1 Trial. <i>Eur Urol</i> 2012;61:826-833. <i>European Urology</i> , 2012, 62, e5-e6.	1.9	3
175	Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey. <i>BJU International</i> , 2012, 110, 692-698.	2.5	39
176	The 6-year attendance of a multidisciplinary prostate cancer clinic in Italy: incidence of management changes. <i>BJU International</i> , 2012, 110, 998-1003.	2.5	47
177	New perspectives in advanced genitourinary malignancies. <i>Tumori</i> , 2012, 98, 267-9.	1.1	2
178	Management of advanced genitourinary tumors. <i>Tumori</i> , 2012, 98, 264-6.	1.1	0
179	Sunitinib and everolimus in pancreatic neuroendocrine tumors. <i>Tumori</i> , 2012, 98, 394.	1.1	2
180	Capecitabine in Combination with Oxaliplatin as First-Line Therapy for Advanced Gastric Cancer: A Case Report. <i>Tumori</i> , 2011, 97, 115-118.	1.1	1

#	ARTICLE	IF	CITATIONS
181	Low dose of ketoconazole in patients with prostate adenocarcinoma resistant to pharmacological castration. <i>BJU International</i> , 2011, 108, 223-227.	2.5	10
182	Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases. <i>BJU International</i> , 2011, 108, E250-E257.	2.5	79
183	Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial. <i>British Journal of Cancer</i> , 2011, 104, 1256-1261.	6.4	66
184	Lecture: management of chemotherapy-induced febrile neutropenia; guidelines and colony stimulating factors. <i>Neurological Sciences</i> , 2011, 32, 217-219.	1.9	2
185	Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1631-1640.	2.4	17
186	Role of sorafenib in renal cell carcinoma: focus on elderly patients. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1689-1692.	2.4	8
187	Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. <i>Annals of Oncology</i> , 2011, 22, 1812-1823.	1.2	124
188	Compassionate Use of Everolimus in a Patient With a Neuroendocrine Tumor: A Case Report and Discussion of the Literature. <i>Oncology Research</i> , 2011, 19, 403-406.	1.5	4
189	Feasibility and activity for sequencing targeted therapies for the treatment of advanced renal cell carcinoma. <i>Medical Oncology</i> , 2010, 27, 1267-1268.	2.5	2
190	Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon- γ compared with sunitinib. <i>British Journal of Cancer</i> , 2010, 102, 80-86.	6.4	60
191	Is It Possible to Optimize the use of Targeted Therapies in the Treatment of Renal Cell Carcinoma?. <i>Tumori</i> , 2010, 96, 794-795.	1.1	2
192	Neoadjuvant targeted therapy in renal cell carcinoma. <i>Nature Reviews Urology</i> , 2010, 7, 1-1.	3.8	1
193	Is it possible to optimize the use of targeted therapies in the treatment of renal cell carcinoma?. <i>Tumori</i> , 2010, 96, 794-5.	1.1	1
194	Pitfalls in the Diagnosis of Neuroendocrine Tumors: Atypical Clinical and Radiological Findings as Cause of Medical Mistakes. <i>Tumori</i> , 2009, 95, 501-507.	1.1	4
195	Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors. <i>Journal of Clinical Oncology</i> , 2009, 27, 319-320.	1.6	8
196	Neuroendocrine tumors (NETs). <i>Clinical Therapeutics</i> , 2009, 31, 2060-2061.	2.5	1
197	From biology to clinical experience: evolution in the knowledge of neuroendocrine tumours. <i>Oncology Reviews</i> , 2009, 3, 79-87.	1.8	3
198	252 RETROSPECTIVE ANALYSIS OF THE SEQUENTIAL USE OF SORAFENIB AND SUNITINIB IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (RCC). <i>European Urology Supplements</i> , 2009, 8, 183.	0.1	19

#	ARTICLE	IF	CITATIONS
199	A randomized, open label, prospective study comparing the association between sorafenib (So) and interleukin-2 (IL-2) versus So alone in advanced untreated renal cell cancer (RCC): Rosorc Trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 5099-5099.	1.6	3
200	Pulmonary Carcinoid Tumours: Indolent but Not Benign. <i>Oncology</i> , 2007, 73, 162-168.	1.9	29
201	Safety and Activity of Sorafenib in Different Histotypes of Advanced Renal Cell Carcinoma. <i>Oncology</i> , 2007, 73, 204-209.	1.9	30
202	Merkel Cell Carcinoma after Liver Transplantation: A Case Report. <i>Tumori</i> , 2007, 93, 323-326.	1.1	10
203	Renal Cell Cancer and Sorafenib: Skin Toxicity and Treatment Outcome. <i>Tumori</i> , 2007, 93, 201-203.	1.1	7
204	Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 59, 637-642.	2.3	218
205	Neuroendocrine Tumors of the Larynx: A Clinical Report and Literature Review. <i>Tumori</i> , 2006, 92, 72-75.	1.1	17
206	Kit Protein (CD 117) and Proliferation Index (Ki-67) Evaluation in Well and Poorly Differentiated Neuroendocrine Tumors. <i>Tumori</i> , 2006, 92, 531-535.	1.1	13
207	Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors. <i>Cancer</i> , 2006, 107, 2474-2481.	4.1	63
208	Kit protein (CD117) and proliferation index (Ki-67) evaluation in well and poorly differentiated neuroendocrine tumors. <i>Tumori</i> , 2006, 92, 531-5.	1.1	8
209	In regard to Kagan: "The multidisciplinary clinic" (<i>Int J Radiat Oncol Biol Phys</i> 2005;61:967-968). <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, 309-310.	0.8	13
210	Safety and Efficacy of Two Different Doses of Capecitabine in the Treatment of Advanced Breast Cancer in Older Women. <i>Journal of Clinical Oncology</i> , 2005, 23, 2155-2161.	1.6	200
211	Is the new WHO classification of neuroendocrine tumours useful for selecting an appropriate treatment?. <i>Annals of Oncology</i> , 2005, 16, 1374-1380.	1.2	67
212	Treatment Options in Hormone-refractory Metastatic Prostate Carcinoma. <i>Tumori</i> , 2004, 90, 535-546.	1.1	34
213	Accuracy and Clinical Correlates of Two Different Methods for Chromogranin A Assay in Neuroendocrine Tumors. <i>International Journal of Biological Markers</i> , 2004, 19, 295-304.	1.8	16
214	Accuracy and clinical correlates of two different methods for chromogranin A assay in neuroendocrine tumors. <i>International Journal of Biological Markers</i> , 2004, 19, 295-304.	1.8	22
215	Levofloxacin: update and perspectives on one of the original "respiratory quinolones"™. <i>Expert Review of Anti-Infective Therapy</i> , 2003, 1, 371-387.	4.4	17
216	Update on the treatment of neuroendocrine tumors. <i>Expert Review of Anticancer Therapy</i> , 2003, 3, 631-642.	2.4	24

#	ARTICLE	IF	CITATIONS
217	Current Treatments of Neuroendocrine Tumors Role of Biotherapy and Chemotherapy. Tumori, 2003, 89, 111-116.	1.1	6
218	Renal Cancer Treatment: A Review of the Literature. Tumori, 2003, 89, 476-484.	1.1	16
219	Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours. Annals of Oncology, 2002, 13, 614-621.	1.2	103
220	A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma. Cancer, 2002, 94, 299-304.	4.1	33
221	Capecitabine: Indications and Future Perspectives in the Treatment of Metastatic Colorectal and Breast Cancer. Tumori, 2001, 87, 364-371.	1.1	8
222	Advances in diagnosis and therapy of neuroendocrine tumors. Expert Review of Anticancer Therapy, 2001, 1, 371-381.	2.4	5
223	Gemcitabine plus vinorelbine as first-line chemotherapy in advanced nonsmall cell lung carcinoma a Phase II trial. Cancer, 2000, 89, 763-768.	4.1	28
224	Fluoropyrimidines in the Treatment of Advanced Neoplastic Diseases: Role and Advantages of UFT. Tumori, 1999, 85, 6-11.	1.1	8
225	Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer, 1999, 86, 858-865.	4.1	249
226	5-fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors. Cancer, 1998, 83, 372-378.	4.1	139
227	Cultural adaptation of the Italian version of the Patient-Reported Outcomes Common Terminology Criteria for Adverse Event (PRO-CTCAE®). Tumori, 0, , 030089162210995.	1.1	3